Edibeck Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Edibeck Therapeutics - overview
Established
2023
Location
Shenzhen, Guangdong, China
Primary Industry
Pharmaceuticals
About
Based in Shenzhen, China, and founded in 2023, Shenzhen Aidibeike Biopharmaceutical Co. , Ltd. , doing business as Edibeck Therapeutics, is a drug discovery company that focuses on CRISPR gene-editing technology. The company holds multiple patents on CRISPR gene-editing.
Its founder and CEO, Mr. Zhenhuang Yang, graduated from University of Lübeck/UKSH, Germany and is an associate researcher at Nanjing Gulou Hospital. In February 2024, the company closed an angel funding led by Cowin Capital. In December 2025, Edibeck Therapeutics closed series A+ funding from returning investor Cowin Capital.
Edibeck Therapeutics is committed to the development of gene-based therapies, focusing on the research and application of foundational gene editing technologies, particularly in Type I CRISPR technology which has been applied to virus removal. The company generates revenue from developing drugs and therapies based on gene-editing technology. The series A+ funding will be used by the company to advance technology transfer and new drug development.
Current Investors
Cowin Capital, Entropy Capital
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.edibeck.cn
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.